1

Merck’s Enlicitide Decanoate Lowers LDL-C in HeFH Adults in Phase 3 CORALreef Trial

News Discuss 
This effect was similar to results from the Phase 3 CORALreef Lipids study. The findings will be presented at the 2025 AHA Scientific Sessions and published in the Journal of the American Medical Association. https://www.coherentmarketinsights.com/news/mercks-enlicitide-decanoate-lowers-ldl-c-in-hefh-adults-1843

Comments

    No HTML

    HTML is disabled


Who Upvoted this Story